Key Points
- CEO Emily Leproust sold 1,687 shares of Twist Bioscience at an average price of $165.49, generating approximately $279,182. The sale covered tax obligations tied to vested equity awards and reduced her stake by 0.27%, leaving her with 618,902 shares.
- Twist reported quarterly revenue of $118.38 million, up 23.2% year over year and above expectations, but its $0.56 loss per share missed estimates. The company remains unprofitable, with analysts expecting a full-year loss.
- TWST has risen sharply toward its 52-week high, while analyst sentiment remains a consensus “Moderate Buy” with an average price target of $103—well below the stock’s recent trading level—highlighting potential valuation and profit-taking risks.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 294 shares of Twist Bioscience stock in a transaction on Monday, September 21st. The stock was sold at an average price of $165.49, for a total transaction of $48,654.06. Following the sale, the senior vice president owned 116,720 shares in the company, valued at $19,315,992.80. This represents a 0.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Twist Bioscience Trading Down 3.7%
Shares of TWST stock opened at $158.50 on Thursday. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $170.66. The stock has a market cap of $9.94 billion, a price-to-earnings ratio of -71.40 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The firm has a fifty day moving average of $123.26 and a 200-day moving average of $85.49.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same period in the previous year, the business posted $0.33 earnings per share. Twist Bioscience's revenue was up 23.2% on a year-over-year basis. On average, equities research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Key Twist Bioscience News
Here are the key news stories impacting Twist Bioscience this week:
- Positive Sentiment: Twist’s partnership with Lilly TuneLab, Eli Lilly’s AI-driven drug-discovery platform, makes Twist a preferred provider of antibody-characterization data and expands its exposure to AI-enabled pharmaceutical research. Twist Bioscience Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership
- Positive Sentiment: The company’s latest quarterly update showed record revenue of $118.4 million, up 23.2% year over year, and higher full-year revenue guidance. These results provide fundamental support for the recent rally, despite a quarterly loss and an earnings miss.
- Neutral Sentiment: TWST recently reached a new 12-month high after its partnership-driven advance, leaving the stock vulnerable to normal consolidation and profit-taking. Twist Bioscience Hits New 12-Month High
- Neutral Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating, although several published price targets remain well below the current market level. This highlights valuation risk after the stock’s substantial appreciation.
- Negative Sentiment: CEO Emily Leproust sold 1,687 shares, while SVP Paula Green and insider Dennis Cho sold 294 and 348 shares, respectively, at approximately $165.49. The transactions were reportedly made to cover tax withholding on vested equity awards, limiting their negative significance, and each executive retained a large stake. SEC insider transaction filings
- Negative Sentiment: A larger recent sale by Leproust—356,546 shares worth approximately $56.3 million—reduced her direct ownership by roughly 36.5%. Although it was executed under a pre-arranged Rule 10b5-1 plan, the scale of the transaction may weigh on momentum investors. Twist Bioscience CEO Emily Leproust Sells Stock
- Negative Sentiment: Reports indicate no insider purchases and 87 insider sales over the past six months. Combined with TWST’s high-growth valuation and ongoing losses, the selling trend increases concerns about near-term profit-taking and downside risk.
Analyst Ratings Changes
TWST has been the topic of a number of recent research reports. Guggenheim reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Monday, August 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a report on Monday. Piper Sandler raised their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, TD Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $103.00.
Read Our Latest Stock Analysis on TWST
Institutional Trading of Twist Bioscience
Hedge funds have recently modified their holdings of the company. QRG Capital Management Inc. acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $277,000. Engineers Gate Manager LP acquired a new stake in Twist Bioscience during the 2nd quarter valued at $3,333,000. Integrated Wealth Concepts LLC acquired a new stake in Twist Bioscience during the 2nd quarter valued at $99,000. Allworth Financial LP raised its position in Twist Bioscience by 54.9% in the 2nd quarter. Allworth Financial LP now owns 601 shares of the company's stock valued at $62,000 after purchasing an additional 213 shares during the last quarter. Finally, Nykredit A S bought a new position in Twist Bioscience in the 2nd quarter valued at $283,000.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.
Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.
Twist was founded in 2013 and is headquartered in South San Francisco, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
